Dasatinib-Blinatumomab for Ph-Positive ALL. Reply
N Engl J Med
.
2021 Jan 28;384(4):384.
doi: 10.1056/NEJMc2033785.
Authors
Robin Foà
1
,
Sabina Chiaretti
1
Affiliation
1
Sapienza University, Rome, Italy rfoa@bce.uniroma1.it.
PMID:
33503352
DOI:
10.1056/NEJMc2033785
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Bispecific*
Dasatinib
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Substances
Antibodies, Bispecific
blinatumomab
Dasatinib